DDO-7263

Overview

DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD).

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Depression | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > NF-κB | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Keap1-Nrf2

Product Information

• Catalog No.: HY-144634
• CAS No.: 2254004-96-9
• Molecular Formula: C14H9F2N3O
• Molecular Weight: 273.24
• Purity: 99.83%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 1.79 mg/mL (6.55 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source